Cidara (CDTX) Rises 14.04% on June 21

Equities Staff  |

Cidara Therapeutics Inc (NASDAQ: CDTX) has gained $0.0666 (14.04%) and sits at $0.54, as of 11:50:41 est on June 21.

214,983 shares have traded hands.

The Company has fallen 5.31% over the last 5 days and shares gained 6.75% over the last 30 days.

Cidara expects its next earnings on 2022-08-11.

For technical charts, analysis, and more on Cidara visit the company profile.

About Cidara Therapeutics Inc

Cidara Therapeutics Inc. isa is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidara's proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California.

To get more information on Cidara Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Cidara Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content